On 22 April 2022 Biogen announced that it had notified the European Medicines Agency (EMA) about the withdrawal of its marketing authorisation application for aducanumab for the treatment of early Alzheimer’s disease. The agency had previously found on 16 December 2021 that the benefits of aducanumab did not outweigh its risks and had therefore recommended…
Category: Alzheimer’s
Dementia Research: New Alzheimer Europe discussion paper
New discussion paper from Alzheimer Europe
Grifols presents latest Alzheimer’s clinical trial data
Neuroimaging shows AMBAR clinical trial’s positive effects in patients with mild-to-moderate Alzheimer’s disease
